Serogroup B Meningococcal Vaccine and Outbreaks
Questions and Answers
Three serogroups, or strains, of meningococcal bacteria (serogroups, B, C, and Y) circulate and cause disease in the United States. In certain outbreaks, vaccination against meningococcal disease is recommended to help stop the disease from spreading. In the United States, vaccines are approved and routinely used against serogroups C and Y (in addition to A and W, which circulate globally), but not B. A serogroup B meningococcal vaccine that is licensed for use in Europe, Canada, and Australia has been considered or used recently in the United States to help control outbreaks of this disease:
- Princeton University Meningococcal Disease Outbreak
- University of California, Santa Barbara Meningococcal Disease Outbreak
Learn more about the serogroup B meningococcal vaccine below.
What is meningococcal disease?
Meningococcal disease can refer to any illness that is caused by the type of bacteria called Neisseria meningitidis, also known as meningococcus. Fewer than 1,000 cases of meningococcal disease occur each year in the United States.
These bacteria can cause serious infections like meningococcal meningitis (infection of the protective membranes of the brain and spinal cord) and meningococcal septicemia (bloodstream infection causing bleeding into the skin and organs).
There are five main serogroups ("strains") of meningococcal bacteria: A, B, C, Y, and W. The most common ones that cause disease in the United States are B, C, and Y. In 2012 there were about 500 total cases of meningococcal disease, and 160 of those cases were caused by serogroup B.
View CDC’s guidance for evaluating and managing meningococcal disease outbreaks.
Safety of the Vaccine
Q: How safe is the vaccine?
A: More than 8,000 infants, children, adolescents, and adults were safely vaccinated with the serogroup B meningococcal vaccine as part of the studies that resulted in its approval in Europe, Canada, and Australia. Like any vaccine, this one can potentially cause a serious problem such as a severe allergic reaction, though the risk of serious harm from the vaccine is extremely small.
Common side effects in adolescents and young adults
The most common side effects take place where the shot was given (in the arm), which can include pain and tenderness, swelling, and hardness of the skin. Other common side effects for adolescents and young adults include nausea, feeling a little run down, and having a headache. These reactions usually last a short amount of time and get better on their own within a few days. Among adolescents, there is also a risk of fainting after getting this vaccine or any shot.
Common side effects in children up to 10 years of age
The most common side effects are loss of appetite, sleepiness, unusual crying, diarrhea, vomiting, rash, fever, and irritability, as well as tenderness, swelling, hardness, and redness of the skin where the shot was given (in the arm or leg). These reactions usually last a short amount of time and get better on their own within a few days.
Q: Does the Food and Drug Administration (FDA) think it’s safe to get this vaccine?
A: Yes. FDA has stayed informed about development of serogroup B meningococcal vaccines over the years and recently reviewed the latest available data. From this review, FDA has concluded that the benefits of using the vaccine to prevent meningococcal disease outweigh the risks of possible adverse events in certain outbreak situations. For example, the FDA allowed its use during the serogroup B meningococcal disease outbreak at Princeton University.
FDA and CDC monitor the safety of the serogroup B meningococcal vaccine whenever the vaccine is allowed to be used to help shorten the duration of an outbreak.
Q: Why is the vaccine referred to as an "investigational new drug"?
A: This is a term FDA uses to describe a medication or vaccine that is not licensed (approved) in the United States, but which may be used in certain specific situations.
Q: Can the vaccine give someone meningococcal disease?
A: No. Since the serogroup B meningococcal vaccine does not include any live bacteria, but is instead made of inactivated parts of the Neisseria meningitidis bacteria, the vaccine cannot give someone meningococcal disease.
Q: Is it safe to get the vaccine right after getting another meningococcal vaccine, like Menveo® or Menactra®, or after getting a flu vaccine?
A: Yes, it is safe to get the vaccine after receiving another meningococcal vaccine or a flu vaccine.
Q: Is there anything someone should tell the doctor or nurse before getting the vaccine?
A: Yes. They should tell the doctor or nurse if they:
- Are not feeling well. If the person has a severe infection with a high temperature, vaccination should be delayed. But the vaccine should be given on time if there is only a minor infection, such as a cold.
- Have a chronic medical problem, like hemophilia.
- Have a severe (life threatening) allergy to any vaccine component.
- Are pregnant or breastfeeding.
Q: Do people recommended to get this vaccine, but who have already gotten a meningococcal vaccine, need this one, too?
A: Yes. People who are recommended to receive the serogroup B meningococcal vaccine need it in addition to the meningococcal vaccine routinely administered in the United States. That vaccine protects against four serogroups ("strains"), known as serogroups A, C, Y, and W, but not against B. The serogroup B meningococcal vaccine helps protect against serogroup B and can only be used during certain situations when allowed by the FDA, like during an outbreak of serogroup B meningococcal disease. During past serogroup B meningococcal disease outbreaks, people have not had the opportunity to get this vaccine because there wasn’t one available or licensed anywhere that would have been effective.
Q: How many doses of the vaccine are needed?
A: Two doses are needed for maximum protection. The second dose should be given one to six months after the first dose (but not sooner).
Q: How long does it take to get protected after getting the first dose of the vaccine?
A: After getting the first dose of the vaccine, it will take about 2 weeks for the body’s immune system to develop enough protection (antibodies) to help prevent serogroup B meningococcal disease. Since that protection declines over time, a second dose is needed to maintain protection. It is critical that high levels of protection are achieved during an outbreak.
Q: Is this an approved vaccine?
A: The serogroup B meningococcal vaccine is not approved in the United States. FDA has allowed the use of the vaccine to help control a specific outbreak at Princeton University under an Investigational New Drug application, which refers to the FDA review process that authorizes use in certain situations of a medication or vaccine that is not licensed (approved) in the United States. FDA considers the circumstances of each outbreak individually when determining if use of the serogroup B meningococcal vaccine should be allowed. Clinical trials in other countries have shown the vaccine to meet safety and efficacy standards to allow licensure in the European Union, Canada, and Australia. Before these countries approved the vaccine’s use, their regulatory agencies — those similar to the FDA in the United States — completed a thorough review of the available data.
Q: Where is the vaccine licensed and how new is it?
A: The vaccine is currently licensed, but not routinely recommended for use, in Europe, Canada, and Australia. The United Kingdom recommends people at high risk of meningococcal disease receive it. The European Union approved its use in January 2013, Australia approved its use in August 2013, and Canada approved its use in December 2013. These countries have higher rates of meningococcal disease caused by serogroup B compared to countries like the United States. Before these countries approved the vaccine’s use, their regulatory agencies — those similar to the FDA in the United States — completed a thorough review and concluded the vaccine was effective and met safety standards. Approvals in additional countries are expected soon.
Q: Will a serogroup B meningococcal vaccine eventually be licensed for use in the United States?
A: It is possible that manufacturers will get this type of vaccine licensed in the United States in the future. In April 2011, an FDA advisory committee discussed the data available at that time about serogroup B meningococcal vaccines and approaches for getting those vaccines licensed in the United States. Questions regarding Novartis’ plans to seek licensure in the United States should be directed to them.
Q: Have vaccines similar to this one been used before?
A: Yes. The vaccine is similar to, but likely more effective than, a serogroup B vaccine (MeNZB) that was used for several years in New Zealand. The vaccine used in New Zealand protected against one type of serogroup B. More than 1.1 million people were vaccinated with MeNZB in New Zealand from 2004-2011, helping to stop a country-wide outbreak of serogroup B meningococcal disease. No unusual pattern or occurrence of serious reactions was seen with the MeNZB vaccine.
The company (Novartis) who makes the serogroup B vaccine produces another meningococcal vaccine (Menveo®) that has been licensed and recommended for use in the United States since 2010 to help protect against serogroups A, C, Y, and W. However, Menveo® does not offer protection against serogroup B. If recommended, people need to get the serogroup B vaccine in order to be best protected during serogroup B outbreaks.
Q: Where has this vaccine been used in the United States?
A: The serogroup B meningococcal vaccine is being used for the first time in the United States under an Investigational New Drug application in response to an outbreak at Princeton University. More than 5,000 Princeton University students received the first dose of the vaccine in December 2013. To date, there have been no unusual patterns or occurrence of serious reactions associated with the vaccine.
Q: When recommended, is the vaccine being offered to conduct a research study?
A: No. The vaccine is being provided for prevention of serogroup B meningococcal disease during specific outbreaks given the lack of an available, adequate, and approved preventive alternative in the United States.
Vaccine Use for Others
Q: Will the vaccine be offered to other people?
A: No. As of this time, the vaccine is only able to be used for groups identified in an Investigational New Drug application as being at increased risk for getting meningococcal disease in specific outbreaks. The vaccine is not broadly available because it is not approved in the United States.
Role of Antibiotics in Meningococcal Outbreaks
Q: Why can't antibiotics be used for everyone instead of the vaccine?
A: Antibiotics are given to close contacts of those who have been diagnosed with meningococcal disease. Anyone who is a close contact of a person with meningococcal disease is at extremely high risk for getting the infection. Close contacts are identified by asking people about the extent of their contact and interactions with the person who got meningococcal disease. For example, living with the person who got sick puts you at high risk, but working together in an office generally does not.
Recommending antibiotics to an entire student body is not an effective strategy. Meningococcal bacteria are spread from person to person and cause "carriage" in the nose and throat. Carriage means that the bacteria live in the nose and throat, but don’t invade your body and make you sick. Most carried strains are unlikely or unable to cause disease. Though certain strains are more likely to cause disease, at any given time only a very small number of people may carry the outbreak strain. If you are exposed to the outbreak strain you either develop disease within a few days or you develop immunity and the carried bacteria disappear from your nose and throat.
If you wanted to try and control an outbreak with antibiotics, you would have to treat every single person at risk in the outbreak at the same time. Otherwise, if one person is still carrying the bacteria in their nose and throat, it can continue to spread since people would not have lasting protection like a vaccine can provide. Even if you can treat everyone at once, antibiotics are about 85% effective at eliminating the carried bacteria in the nose and throat, but not 100%. The strain could still circulate among a student population. For the same reason, it is not possible to test everyone and treat the carriers with antibiotics.
On the other hand, the vaccine helps protect people for a much longer period of time. Even if you are exposed, the vaccine helps protect you against the bacteria. It is also possible for the vaccine to decrease or stop spread of the bacteria, which would help protect the community as a whole by stopping carriage in the nose and throat.
In addition, about 1 in every 100 people is allergic to an antibiotic. Some may not even know it. Treating many people unnecessarily with antibiotics also carries risks, possibly causing more harm than good. To help prevent the growing threat of antibiotic resistance, it is critical that antibiotics only be used when necessary and appropriate.
Q: Should people at institutions currently experiencing an outbreak take antibiotics before travelling home in order to protect their family and friends in case they are carrying meningococcus bacteria?
A: No. CDC does not recommend that students, staff, or faculty take antibiotics based on concern for exposing others back home. We know from prior experience with meningococcal disease outbreaks at universities that the risk of the outbreak spreading outside to the community or to family members is very low. Public health authorities carefully investigate all reported cases of meningococcal disease.
At any given time during an outbreak, very few individuals carry the outbreak strain of these bacteria in their noses and throats. Treating many people unnecessarily with antibiotics carries risks, possibly causing more harm than good. To help prevent the growing threat of antibiotic resistance, it is critical that antibiotics only be used when necessary and appropriate. The resistance might occur in meningococcus bacteria or in other bacteria the person carries. In addition, antibiotics wipe out the "good" bacteria that protect us from colonization and infection with more harmful microbes. Plus, about 1 in every 100 people is allergic to an antibiotic.
Contact with Institutions Experiencing Serogroup B Outbreaks
Q: Should students at institutions experiencing serogroup B meningococcal disease outbreaks cancel their plans or be quarantined until the outbreak is over?
A: We recognize that when cases of meningococcal disease occur, there is increased concern about the potential spread of disease and desire to take appropriate steps to prevent additional cases. There is no evidence that family members and the community are at increased risk of getting meningococcal disease from casual contact with students, faculty, or staff at institutions experiencing outbreaks. Therefore, CDC does not recommend curtailing social interactions or canceling travel plans as a preventive measure for meningococcal disease. Instead, we continue to recommend that people remain vigilant to the symptoms of meningococcal disease and seek treatment immediately if they experience any of those symptoms.
Q: Should outside sports teams, clubs, or other people who plan to visit or host students from institutions experiencing an outbreak of serogroup B meningococcal disease cancel their plans?
A: No, plans should not be cancelled or delayed. Please see more information about this question here [2 pages].
- Bai X, Findlow J, Borrow R. Recombinant protein meningococcal serogroup B vaccine combined with outer membrane vesicles. Expert Opin Biol Ther. 2011Jul;11(7):969-85.
- Donnelly J, Medini D, Boccadifuoco G, Biolchi A, Ward J, Frasch C, et al. Qualitative and quantitative assessment of meningococcal antigens to evaluate the potential strain coverage of protein-based vaccines. Proc Natl Acad Sci U S A. 2010 Nov 9;107(45):19490-5.
- Dull P, Bai X, Bazaz R, Nolan K, Nazir A, Karsten A, et al. Serum bactericidal antibody levels following quadrivalent conjugate(MenACWY-CRM) or serogroup B (4CMenB) meningococcal vaccines in a Phase 3 study to evaluate the effect of vaccination on pharyngeal carriage of N. meningitidis in young adults. Poster session presented at: Meningitis and Septicaemia in Children and Adults 2013; 2013 November 5-6;London, England, UK.
- Frosi G, Biolchi A, Lo Sapio M, Rigat F, Gilchrist S, Lucidarme J, et al. Bactericidal antibody against a representative epidemiological meningococcal serogroup B panel confirms that MATS underestimates 4CMenB vaccine strain coverage. Vaccine. 2013 Oct 9;31(43):4968-74.
- Martin NG, Snape MD. A multicomponent serogroup B meningococcal vaccine is licensed for use in Europe: what do we know, and what are we yet to learn? Expert Rev Vaccines. 2013 Aug;12(8):837-58.
- Pizza M, Scarlato V, Masignani V, Giuliani MM, Aricò B, Comanducci M, et al. Identification of vaccine candidates against serogroup B meningococcus by whole-genome sequencing. Science. 2000 Mar 10;287(5459):1816-20.
- Read RC, Baxter D, Chadwick DR, Faust SN, Finn A, Gordon SB, et al. Impact of quadrivalent conjugate (MenACWY-CRM) and serogroup B (4CMenB) meningococcal vaccines on meningococcal carriage in English university students. Poster session presented at: Meningitis and Septicaemia in Children and Adults 2013; 2013 November 5-6;London, England, UK.
- Santolaya ME, O'Ryan M, Valenzuela MT, Prado V, Vergara RF, Muñoz A, et al. Persistence of antibodies in adolescents 18-24 months after immunization with one, two, or three doses of 4CMenB meningococcal serogroup B vaccine. Hum Vaccin Immunother. 2013 Jun 28;9(11).
- Santolaya ME, O'Ryan ML, Valenzuela MT, Prado V, Vergara R, Muñoz A, et al. Immunogenicity and tolerability of a multicomponent meningococcal serogroup B (4CMenB) vaccine in healthy adolescents in Chile: a phase 2b/3 randomised, observer-blind, placebo-controlled study. Lancet. 2012 Feb 18;379(9816):617-24.
- Vogel U, Taha MK, Vazquez JA, Findlow J, Claus H, Stefanelli P, et al. Predicted strain coverage of a meningococcal multicomponent vaccine (4CMenB) in Europe: a qualitative and quantitative assessment. Lancet Infect Dis. 2013 May;13(5):416-25.
Images and logos on this website which are trademarked/copyrighted or used with permission of the trademark/copyright or logo holder are not in the public domain. These images and logos have been licensed for or used with permission in the materials provided on this website. The materials in the form presented on this website may be used without seeking further permission. Any other use of trademarked/copyrighted images or logos requires permission from the trademark/copyright holder...more
This graphic notice means that you are leaving an HHS Web site. For more information, please see the Exit Notification and Disclaimer policy.